WESTON, Fla., April 19, 2017 /PRNewswire/ -- Cantex Pharmaceuticals Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancers and other life-threatening disorders, today announced that Stephen G. Marcus, M.D., Chief Executive Officer, will present an overview entitled, "CX-02: Targeting Cancers of the Nervous System in Adults and Children" at the World Orphan Drug Congress USA. The event will take place April 19-21, 2017 at the Washington Marriott Wardman Park in Washington, DC.
Stephen Marcus, M.D., Chief Executive Officer of Cantex Pharmaceuticals, Inc., stated, "Clinical and pre-clinical evidence strongly suggests that CX-02 has cancer-cell killing effects against glioblastoma, breast cancer, prostate cancer, and other forms of cancer. As we advance CX-02 into Phase II trials for recurrent glioblastoma, an aggressive brain cancer, events such as the World Orphan Drug Congress offer an important opportunity to interact with key stakeholders in the orphan drug community."
CX-02 is a proprietary combination of disulfiram + copper with several non-overlapping cancer cell-killing mechanisms, including proteasome inhibition and induction of the cancer cell-killing reactive oxygen radicals. Pre-clinical studies of CX-02 have indicated a striking glioblastoma stem cell-killing effect and the ability of disulfiram + copper to reverse temozolomide resistance.
CX-02 has been granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration's Office of Orphan Products Development. In addition, Cantex plans to initiate further clinical trials of CX-02 in 2017 in metastatic prostate cancer and metastatic breast cancer.
About Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancers and other life-threatening disorders. Cantex's CX-02 is a proprietary combination of disulfiram + copper. CX-02 is currently in a Phase II clinical trial for recurrent glioblastoma, with plans to initiate additional Phase II trials in metastatic prostate cancer and metastatic breast cancer in the second half of 2017 and in 2018. Cantex's second clinical stage product, CX-01, is being developed for the treatment of acute myeloid leukemia (AML) and other blood disorders. A randomized Phase IIB trial of CX-01 in newly diagnosed AML and a Phase II trial of CX-01 in patients with myelodysplastic syndrome are currently enrolling patients. For more information, please visit www.cantex.com.
SOURCE Cantex Pharmaceuticals, Inc.